Comparing the current results to its competitors, Xilio Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 131.22 % year on year. The sales growth was above Xilio Therapeutics Inc 's competitors' average revenue growth of 6.39 %, achieved in the same quarter.
Xilio Therapeutics Inc , slower than the average decrease reported by the company's competitors of -66.82 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -66.82 %
Xilio Therapeutics Inc 's Comment on Competition and Industry Peers
The company utilizes a proprietary platform technology and masking approach in the development of cancer treatments. It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Some competitors, individually or with strategic partners, possess greater financial, technical, and human resources, potentially leading to advantages in research and development, manufacturing, clinical trials, regulatory approval, and market acceptance. Additionally, merger and acquisition activity within the biotechnology and biopharmaceutical industries may consolidate resources among fewer competitors, who also compete for qualified scientific and management personnel.
March 28, 2024
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramFOSTER CITY, Calif. and WALTHAM, Mass., March 28, 2024 - Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) have recently revealed a groundbreaking exclusive license agreement that showcases their commitment to advancing cancer treatment. The agreement allows Gilead to develop and commercialize Xilio s Phase 1 tumor-activated IL-12 program, XTX301, a clinical-stage IL-12 molecule with immense potential to treat a vast range of cancers.This partnership marks a significant milestone in the fight against cancer, as the tumor-activated IL-12 program presents a unique approach to harnessing the powe...
Apellis Pharmaceuticals Inc operates under a business model that focuses on the research, development, and commercialization of novel therapies for various medical conditions, with a particular emphasis on complement immunotherapy. They aim to bring innovative drugs to market that can positively impact patients' lives worldwide.
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Immunome Inc is a biotechnology company that focuses on developing novel immunotherapies. Their business model revolves around leveraging their proprietary discovery engine to identify therapeutic antibodies for infectious diseases and cancer. By collaborating with partners and through their own clinical development efforts, they aim to bring these promising treatments to the market.
Oculis Holding Ag is a pharmaceutical company that specializes in developing and commercializing innovative ophthalmic treatments. Their business model revolves around conducting in-depth research and development to formulate eye medications that target various ocular diseases. They then seek regulatory approvals and form strategic partnerships to manufacture and distribute their products globally, aiming to improve eye health and provide effective treatment options for patients.
Third Harmonic Bio Inc's business model centers around developing and commercializing innovative therapeutic solutions through the utilization of bioinformatics and genomics.
Sources:
Xilio Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Xilio Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
